Hao Rubin, Sun Bixi, Yang Lihua, Ma Chun, Li Shuling
Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, ChangChun, Jilin, China.
School of Pharmaceutical Sciences, Jilin University, ChangChun, Jilin, China.
Drug Deliv. 2020 Dec;27(1):772-781. doi: 10.1080/10717544.2020.1760960.
Effective nose-to-brain delivery needs to be developed to treat neurodegenerative diseases. Regulating miR-124 can effectively improve the symptoms of ischemic brain injury and provide a certain protective effect from brain damage after cerebral ischemia. We used rat models of middle cerebral artery occlusion (t-MCAO) with ischemic brain injury, and we delivered RVG29-NPs-miR124 intranasally to treat neurological damage after cerebral ischemia. Rhoa and neurological scores in rats treated by intranasal administration of RVG29-PEG-PLGA/miRNA-124 were significantly lower than those in PEG-PLGA/miRNA-124 nasal administration and RVG29-PLGA/miRNA-124 nasal administration group treated rats. These results indicate that the nose-to-brain delivery of PLGA/miRNA-124 conjugated with PEG and RVG29 alleviated the symptoms of cerebral ischemia-reperfusion injury. Thus, nasal delivery of RVG29-PEG-PLGA/miRNA-124 could be a new method for treating neurodegenerative diseases.
需要开发有效的鼻脑给药方式来治疗神经退行性疾病。调节miR-124可有效改善缺血性脑损伤症状，并对脑缺血后脑损伤起到一定的保护作用。我们使用了具有缺血性脑损伤的大脑中动脉闭塞大鼠模型（t-MCAO），并通过鼻内给予RVG29-NPs-miR124来治疗脑缺血后的神经损伤。经鼻内给予RVG29-PEG-PLGA/miRNA-124治疗的大鼠的Rhoa和神经学评分显著低于经PEG-PLGA/miRNA-124鼻内给药和RVG29-PLGA/miRNA-124鼻内给药组治疗的大鼠。这些结果表明，与PEG和RVG29偶联的PLGA/miRNA-124的鼻脑给药减轻了脑缺血再灌注损伤的症状。因此，鼻内给予RVG29-PEG-PLGA/miRNA-124可能是治疗神经退行性疾病的一种新方法。
